Completed PHASE1 INTERVENTIONAL NCT00089453

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma

Sponsor: University of Arkansas

Conditions Multiple Myeloma

Interventions Auto Graft Bortezomide Cyclophosphamide Dexamethasone Fludarabine Infusion #1 Infusion #2 Interleukin Leukapheresis Leukapheresis #2 Melphalan

Updated 5 times since 2017 Last updated: Apr 17, 2012 Started: Sep 30, 2003 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00089453, this PHASE1 trial focuses on Multiple Myeloma and remains completed. Sponsored by University of Arkansas, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Arkansas

Data source: University of Arkansas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Little Rock, United States